Roswell Park Research on Survivin Opens Up New Avenues for Cancer Immunotherapy


Molecule can exist on tumor surface, suggesting new opportunities for CAR T and antibody-based therapies

BUFFALO, N.Y. — New research from Roswell Park Comprehensive Cancer Center and MimiVax LLC shows that one of the most commonly occurring molecules in cancer cells may be an attractive target for a broad range of immunotherapy approaches, including CAR T, or chimeric antigen receptor T-cell therapy. The findings have been published online ahead of print in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR).

Survivin is a cell-survival protein highly expressed by many types of cancer, including many glioma, lung, pancreatic, breast and neuroendocrine tumors and some forms of multiple myeloma, lymphoma and leukemia. Emerging vaccine approaches developed at Roswell Park and targeting the survivin protein may be more effective than standard therapy alone for some patients with glioblastoma.

Previously, survivin was thought to be present only inside the cancer cell, where some types of immunotherapy could not reach it. The new preclinical study is the first to report that this protein can be found on the surface of cancer cells, which means that certain forms of immunotherapy targeting the protein could be effective against cancer cells.

“We’ve shown through our clinical trials of SurVaxM immunotherapy that survivin-targeting vaccines will stimulate both T-lymphocyte and antibody responses against survivin,” says senior author Michael Ciesielski, PhD, Assistant Professor in the Department of Neurosurgery at Roswell Park. “Through this latest study, we have now discovered that antibodies that target cell-surface survivin have distinct therapeutic potential.”

This observation suggests that antibody-based treatment approaches, including survivin CAR T-cell therapy, could be used to target both solid and liquid tumors — a finding that could help broaden the applications for CAR T therapies generally. Current FDA-approved CAR-T therapies are limited to treatments for liquid/hematological cancers.

“We’ve dedicated more than a decade to studying survivin as a target for cancer immunotherapy. This work has opened up a variety of new options for using different forms of immunotherapy for hard-to-treat cancers,” says Robert Fenstermaker, MD, Chair of Roswell Park’s Department of Neurosurgery and lead author on the newly published study. “CAR T cells and antibody approaches are highly attractive because they have the potential to deliver potent therapy to patients whose cancers have survivin, but not other conventional targets, on their surface.”

The study, “Survivin Monoclonal Antibodies Detect Survivin Cell Surface Expression and Inhibit Tumor Growth in vivo,” is available at The work was funded in part by support from the American Cancer Society, Philip H. Hubbell, the Linda Scime Endowment, the National Cancer Institute (project no. P30CA016056, the NCI’s core grant to Roswell Park), MimiVax LLC and by donations to Roswell Park.